Gross margin for FY23 is expected to range from 69%-70% and adjusted operating expenses are expected to range between $415M-$425M. Adjusted EBITDA margin for FY23 is expected to range from approximately negative 0.5%-0.5% of revenues.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IRTC:
- iRhythm Technologies Announces Fourth Quarter and Full Year 2022 Financial Results
- iRhythm Technologies to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
- iRhythm initiated with an Overweight at Wells Fargo
- iRhythm shares preliminary Q4 highlights, business update
- iRhythm Technologies Shares Preliminary Fourth Quarter 2022 Highlights and Business Update at the 41st Annual J.P. Morgan Healthcare Conference
